Keystone Investors PTE Ltd. Acquires Shares of 45,432 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Key Points

• Keystone Investors PTE Ltd. acquired 45,432 shares of Teva Pharmaceutical Industries Ltd., valued at approximately $698,000, according to a recent filing with the SEC.
• Various institutional investors have increased their stakes in Teva, with King Wealth Management Group boosting its holdings by 1,106.9% in the first quarter alone.
• Analyst ratings for Teva Pharmaceutical have improved, with Goldman Sachs and JPMorgan Chase both issuing buy ratings and raising their price targets for the stock.

Keystone Investors PTE Ltd. acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 45,432 shares of the company's stock, valued at approximately $698,000.

Several other institutional investors have also recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Teva Pharmaceutical Industries by 6.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 861,329 shares of the company's stock worth $13,239,000 after purchasing an additional 53,443 shares during the last quarter. Headlands Technologies LLC raised its holdings in Teva Pharmaceutical Industries by 428.7% in the 1st quarter. Headlands Technologies LLC now owns 31,642 shares of the company's stock valued at $486,000 after acquiring an additional 25,657 shares during the last quarter. Deutsche Bank AG raised its holdings in Teva Pharmaceutical Industries by 16.9% in the 1st quarter. Deutsche Bank AG now owns 2,589,607 shares of the company's stock valued at $39,802,000 after acquiring an additional 375,064 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Teva Pharmaceutical Industries by 28.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,324,936 shares of the company's stock valued at $20,364,000 after acquiring an additional 296,012 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $475,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 0.3%

Shares of TEVA stock traded up $0.05 on Friday, reaching $16.34. 9,533,492 shares of the stock were exchanged, compared to its average volume of 13,038,851. The stock has a market cap of $18.74 billion, a P/E ratio of -102.13, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The firm has a 50 day moving average of $16.72 and a two-hundred day moving average of $16.39. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same period in the prior year, the firm posted $0.61 EPS. The business's revenue for the quarter was up .3% on a year-over-year basis. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Buying and Selling

In related news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 65,001 shares of company stock valued at $996,958. Company insiders own 0.49% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. UBS Group cut their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, Bank of America boosted their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.